tiprankstipranks
Immutep Ltd Reports Promising Results in Sarcoma Trial
Company Announcements

Immutep Ltd Reports Promising Results in Sarcoma Trial

Immutep Ltd (AU:IMM) has released an update.

Don't Miss our Black Friday Offers:

Immutep Ltd has unveiled promising Phase II trial results for its novel combination therapy involving eftilagimod alpha, pembrolizumab, and radiotherapy in treating soft tissue sarcoma. The trial demonstrated a significant increase in tumor hyalinization, suggesting improved outcomes and survival rates for patients. With over 71% of participants showing a pathologic response, the therapy showcases potential in addressing this challenging cancer type.

For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskImmutep Ltd Sees Increased Stake from Regal Funds
TheFlyImmutep price target raised to $7 from $6 at Baird
TheFlyImmutep announces data from INSIGHT-003 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App